Sangamo Therapeutics, Inc.
PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
Last updated:
Abstract:
Described herein are engineered nucleases specific for PD1 gene target sites, the nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity for PD1 gene target sites is increased.
Status:
Application
Type:
Utility
Filling date:
18 Sep 2019
Issue date:
14 Oct 2021